BWA
RARE icon

Basecamp Wealth Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

Basecamp Wealth Advisors’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27K Sell
38
-64
-63% -$1.59K ﹤0.01% 1462
2026
Q1 		$2.14K Buy
102
+85
+500% +$1.91K ﹤0.01% 1383
2025
Q4 		$391 Buy
+17
New +$559 ﹤0.01% 1664

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Basecamp Wealth Advisors's RARE Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 63% in Q2 2026, selling an estimated $1.59K and leaving 38 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1462.

Basecamp Wealth Advisors first reported a position in RARE in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.14K in Q1 2026. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Basecamp Wealth Advisors held 38 shares of Ultragenyx Pharmaceutical worth $1.27K as of Q2 2026.
  • Basecamp Wealth Advisors sold 64 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $1.59K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1462 holding.
  • Basecamp Wealth Advisors first reported a position in Ultragenyx Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Ultragenyx Pharmaceutical position peaked at $2.14K in Q1 2026.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.